Archive for August 2018

Predictive Factors of Visual Outcome for Vitreomacular Traction Syndrome After Vitrectomy

Most patients of VMT gained significant functional and anatomical improvements after vitrectomy. Group 1 optical coherence tomography pattern, shorter symptom duration, and younger age are significant predictive factors of better visual outcome.

“Predictive Factors of Visual Outcome for Vitreomacular Traction Syndrome After Vitrectomy”

Retina 38:1533-1540, 2018
Chang-Sue Yang, MD, MHA; Ming-Hung Hsieh, MD; Yu-Fan Chang, MD; Chiao-Yu Wang, MD; Shih-Jen Chen, MD, PhD

Full Paper: Predictive Factors of Visual Outcome for Vitreomacular Traction Syndrome After Vitrectomy

Icon - PDF
Download (365K PDF)

Page

Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid

In a real-world setting, patients with cataracts and wet age-related macular degeneration underwent treatment for age-related macular degeneration fluid and surgery for cataracts. These patients did well postoperatively with no worsening of their neovascular process.

“Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid”

Am. J. Ophthalmol 192:91-97, August 2018
Matthew R. Starr; Michael A. Mahr; Andrew J. Barkmeier; Raymond Iezzi; Wendy M. Smith; Sophie J. Bakri

Full Paper: Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid

Icon - PDF
Download (201K PDF)

Page

Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa

There are no approved drug treatments for autosomal-dominant retinitis pigmentosa.
 
A study of oral Valproic acid (VPA) does not support the use of VPA in the treatment of autosomal-dominant retinitis pigmentosa.
 
The lessons learned from a trial of Valproic acid are:

  • Rigorous evaluation of drug treatment for retinitis pigmentosa is necessary.
  • FDA-approved drugs for other uses can have major adverse effects.
  • Patients vary greatly in their rates of progression of retinitis pigmentosa with identical gene mutations.

“Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa”
Lessons Learned from a Trial of Valproic Acid

JAMA Ophthalmol 136:857-858, August 2018
Brian P. Brooks, MD, PhD; Brett Jeffrey, PhD

Full Paper: Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa_08-13-18

Icon - PDF
Download (113K PDF)

Page